CN1211335C - 抑制hivtat反式激活作用的化合物 - Google Patents
抑制hivtat反式激活作用的化合物 Download PDFInfo
- Publication number
- CN1211335C CN1211335C CNB951960350A CN95196035A CN1211335C CN 1211335 C CN1211335 C CN 1211335C CN B951960350 A CNB951960350 A CN B951960350A CN 95196035 A CN95196035 A CN 95196035A CN 1211335 C CN1211335 C CN 1211335C
- Authority
- CN
- China
- Prior art keywords
- compound
- structural formula
- cells
- follows
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/316,341 | 1994-09-30 | ||
| US08/316,341 US6365787B1 (en) | 1994-09-30 | 1994-09-30 | Compounds for the suppression of HIV TAT transactivation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100743359A Division CN100413835C (zh) | 1994-09-30 | 1995-09-22 | 抑制hiv tat反式激活作用的化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1162301A CN1162301A (zh) | 1997-10-15 |
| CN1211335C true CN1211335C (zh) | 2005-07-20 |
Family
ID=23228649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100743359A Expired - Fee Related CN100413835C (zh) | 1994-09-30 | 1995-09-22 | 抑制hiv tat反式激活作用的化合物 |
| CNB951960350A Expired - Fee Related CN1211335C (zh) | 1994-09-30 | 1995-09-22 | 抑制hivtat反式激活作用的化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100743359A Expired - Fee Related CN100413835C (zh) | 1994-09-30 | 1995-09-22 | 抑制hiv tat反式激活作用的化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6365787B1 (enExample) |
| EP (1) | EP0783474B1 (enExample) |
| JP (2) | JP3966900B2 (enExample) |
| CN (2) | CN100413835C (enExample) |
| AT (1) | ATE403635T1 (enExample) |
| AU (1) | AU700481B2 (enExample) |
| CA (1) | CA2200991C (enExample) |
| DE (1) | DE69535804D1 (enExample) |
| ES (1) | ES2312168T3 (enExample) |
| WO (1) | WO1996010549A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
| WO1999017609A1 (en) * | 1997-10-07 | 1999-04-15 | Larreacorp, Ltd. | Nontoxic extract of larrea tridentata and method of making the same |
| US6608108B2 (en) | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| US20030219407A1 (en) | 2002-05-15 | 2003-11-27 | The Regents Of The University Of California | RNA silencing in animals as an antiviral defense |
| US20060141029A1 (en) * | 2003-05-20 | 2006-06-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
| WO2004112695A2 (en) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceutical Llc | Methods and compositions for delivery of catecholic butanes for treatment of obesity |
| US7728036B2 (en) | 2003-05-20 | 2010-06-01 | Erimos Pharmaceuticals, Llc | Methods for delivery of catecholic butanes for treatment of tumors |
| CN100440843C (zh) * | 2004-05-12 | 2008-12-03 | 华为技术有限公司 | 一种环网及其业务实现方法 |
| US8440648B2 (en) * | 2004-07-20 | 2013-05-14 | Erimos Pharmaceuticals Llc | Methods and compositions for treatment of intraepithelial neoplasia |
| US20080096967A1 (en) * | 2005-01-27 | 2008-04-24 | Erimos Pharmaceuticals Llc | Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals |
| CN101150956B (zh) * | 2005-01-27 | 2013-04-17 | 埃里莫斯医药品有限公司 | 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方 |
| EP1996174A2 (en) * | 2006-02-23 | 2008-12-03 | Erimos Pharmaceuticals LLC | Methods of treating influenza viral infections |
| US9067875B2 (en) | 2006-10-02 | 2015-06-30 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| EP2076252B1 (en) * | 2006-10-02 | 2014-04-02 | Erimos Pharmaceuticals LLC | Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| MX343303B (es) * | 2007-05-11 | 2016-11-01 | Convatec Tech Inc * | Aparato de ostomia. |
| US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| MX2011004824A (es) * | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
| WO2012096934A2 (en) * | 2011-01-10 | 2012-07-19 | The Scripps Research Institute | Inhibitors of retroviral replication |
| WO2013116821A1 (en) * | 2012-02-03 | 2013-08-08 | The Johns Hopkins University | Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer |
| SG11201500397XA (en) * | 2012-07-18 | 2015-03-30 | Univ Johns Hopkins | Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| EP3044593A4 (en) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008294A (en) | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
| US5276060A (en) * | 1979-06-19 | 1994-01-04 | Block/Chemex, G.P. | Methods of treating tumors with compositions of catecholic butanes |
| DE3009542A1 (de) | 1980-03-13 | 1981-09-24 | Henkel KGaA, 4000 Düsseldorf | Desodorierende kosmetische zusammensetzungen |
| US4774229A (en) | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
| US4880637A (en) * | 1985-02-11 | 1989-11-14 | Chemex Pharmaceuticals, Inc. | Compositions of catecholic butanes with zinc |
| FR2632956B2 (fr) * | 1988-05-13 | 1991-07-12 | Pasteur Institut | Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus |
| US5559149A (en) | 1990-01-29 | 1996-09-24 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions containing retinoids |
| US5195965A (en) * | 1991-03-07 | 1993-03-23 | Shantha Totada R | Method and apparatus for localized treatment of human viral infections and cancers |
| US5646186A (en) | 1994-05-17 | 1997-07-08 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
| US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
| US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
| US6071949A (en) | 1995-03-14 | 2000-06-06 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
| US5837252A (en) * | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
| US5827898A (en) | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| AU736587B2 (en) | 1996-11-20 | 2001-08-02 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
-
1994
- 1994-09-30 US US08/316,341 patent/US6365787B1/en not_active Expired - Lifetime
-
1995
- 1995-09-22 DE DE69535804T patent/DE69535804D1/de not_active Expired - Fee Related
- 1995-09-22 CN CNB2005100743359A patent/CN100413835C/zh not_active Expired - Fee Related
- 1995-09-22 CN CNB951960350A patent/CN1211335C/zh not_active Expired - Fee Related
- 1995-09-22 EP EP95933830A patent/EP0783474B1/en not_active Expired - Lifetime
- 1995-09-22 AU AU36339/95A patent/AU700481B2/en not_active Ceased
- 1995-09-22 JP JP51184496A patent/JP3966900B2/ja not_active Expired - Lifetime
- 1995-09-22 AT AT95933830T patent/ATE403635T1/de not_active IP Right Cessation
- 1995-09-22 WO PCT/US1995/011779 patent/WO1996010549A1/en not_active Ceased
- 1995-09-22 CA CA002200991A patent/CA2200991C/en not_active Expired - Fee Related
- 1995-09-22 ES ES95933830T patent/ES2312168T3/es not_active Expired - Lifetime
-
1996
- 1996-04-04 US US08/627,588 patent/US5663209A/en not_active Expired - Lifetime
-
1997
- 1997-06-25 US US08/882,499 patent/US6291524B1/en not_active Ceased
-
2003
- 2003-09-17 US US10/664,050 patent/USRE40246E1/en not_active Expired - Lifetime
-
2006
- 2006-07-04 JP JP2006184646A patent/JP2006273869A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ATE403635T1 (de) | 2008-08-15 |
| CN1762951A (zh) | 2006-04-26 |
| US5663209A (en) | 1997-09-02 |
| WO1996010549A1 (en) | 1996-04-11 |
| AU700481B2 (en) | 1999-01-07 |
| JP2006273869A (ja) | 2006-10-12 |
| EP0783474A4 (enExample) | 1997-08-27 |
| CA2200991A1 (en) | 1996-04-11 |
| USRE40246E1 (en) | 2008-04-15 |
| CN1162301A (zh) | 1997-10-15 |
| US6291524B1 (en) | 2001-09-18 |
| EP0783474A1 (en) | 1997-07-16 |
| CA2200991C (en) | 2007-07-10 |
| JPH10509421A (ja) | 1998-09-14 |
| ES2312168T3 (es) | 2009-02-16 |
| US6365787B1 (en) | 2002-04-02 |
| JP3966900B2 (ja) | 2007-08-29 |
| EP0783474B1 (en) | 2008-08-06 |
| CN100413835C (zh) | 2008-08-27 |
| DE69535804D1 (de) | 2008-09-18 |
| AU3633995A (en) | 1996-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1211335C (zh) | 抑制hivtat反式激活作用的化合物 | |
| KR101567633B1 (ko) | 감귤 미성숙과 추출물, 또는 시네프린 또는 이의 염을 유효성분으로 포함하는 염증성 피부질환 치료 또는 예방용 조성물 | |
| WO1996010549A9 (en) | Compounds for the suppression of hiv tat transactivation | |
| GB2450190A (en) | Cyclohexenones from Antrodia Camphorata for use in the treatment of autoimmune disease | |
| EP2221291B1 (en) | Cyclohexenone compounds from antrodia camphorata and pharmaceutical compositions thereof useful for treating autoimmune diseases | |
| US10143673B2 (en) | Active fraction of a polar solvent extract from the latex of euphorbiaceae plants | |
| CN1620305A (zh) | 诱导凋亡的方法和诱导凋亡的组合物 | |
| JP5203644B2 (ja) | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 | |
| Nemoto et al. | Synthesis of highly water-soluble fibrate derivatives via BGLation | |
| HK1090023A (en) | Compounds for the suppression of hiv tat transactivation | |
| US5989555A (en) | Extracts of Larrea tridentata having antiviral activity and their use for treating viral infections | |
| JP5561647B2 (ja) | 生体防御機能因子の発現亢進剤 | |
| Garattini et al. | Comparison of the plasma levels of fenfluramine in rats after a toxic dose and in man after a maximal therapeutic dose | |
| TW201018462A (en) | Novel mixture and compounds from mycelia of antrodia camphorata having hepatoprotection, anti-inflammatory and anti-tumor activities | |
| Qian et al. | From natural product to clinical trials: Bevirimat, a plant-derived anti-AIDS drug | |
| JPH07112931A (ja) | エプスタイン−バーウイルス活性化抑制剤 | |
| DE19908766C2 (de) | Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien | |
| CN118344432A (zh) | 环肽生物碱类化合物及其制备方法和应用 | |
| CN101041061A (zh) | 一种抗乙型肝炎病毒的药物组合物及其制备方法 | |
| HK1124526A (en) | Active fraction of a polar solvent extract from the latex of euphorbiaceae plants | |
| CN101257912A (zh) | 大戟科植物乳汁的极性溶剂提取物的活性级份 | |
| ZA200108326B (en) | Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof. | |
| JP2013075882A (ja) | 生体防御機能因子の発現亢進剤 | |
| JPH03287528A (ja) | 発癌予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050720 Termination date: 20091022 |